Please login to the form below

Not currently logged in
Email:
Password:

Merrimack

This page shows the latest Merrimack news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack

French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by second-line pancreatic cancer therapy Onivyde. ... The deal includes Onivyde (liposomal irinotecan) and Merrimack's generic version of Doxil (liposomal

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit

  • FDA approves Merrimack's pancreatic cancer drug FDA approves Merrimack's pancreatic cancer drug

    Onivyde improves overall survival rates. The FDA has approved Merrimack's Onivyde for the treatment of advanced pancreatic cancer. ... Biopharmaceutical science company Baxalta has also payed $62.5m to Merrimack as Onviyde enters phase II trials as a

  • Baxter and Merrimack file pancreatic cancer drug in EU Baxter and Merrimack file pancreatic cancer drug in EU

    Baxter and Merrimack Pharma have filed for approval of their pancreatic cancer therapy MM-398 in the EU, a few days after the FDA started a priority review of the drug. ... The FDA has already given the drug priority review status and Merrimack and Baxter

  • Global pancreatic cancer market to treble in value Global pancreatic cancer market to treble in value

    Other drugs marked out by GlobalData as having significant sales potential include Threshold Pharmaceuticals/Merck's TH-302 and Merrimack Pharmaceuticals' MM-398.  .

  • Eastern Europe targeted

    260. PharmaEngine/Merrimack. MM398 in oncology. Licence. 220. CytRx/Orphazyme. Molecular chaperone assets for rare genetic lysosomal diseases.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics